Glycemic Control and Safety of PEG-Loxenatide Versus Semaglutide in Type 2 Diabetes

510 matched patient pairs from a two-center Chinese retrospective cohort study compare high-dose PEG-Loxenatide and semaglutide. The data includes changes in HbA1c, body weight, BMI, LDL-C, systolic blood pressure, and eGFR measured at 3, 6, 12, and 24 months. The study was authored by Zelin Yu and published in 2026.

Use Cases

• Compare HbA1c change from baseline between PEG-Loxenatide and semaglutide treatment groups across 24 months.
• Analyze body weight and BMI improvement differences, where semaglutide showed significant superiority.
• Assess the relationship between adverse drug events, specifically gastrointestinal symptoms, and the treatment group during the first 3 months.
• Model the impact of treatment on cardiorenal indicators like LDL-C, systolic blood pressure, and estimated glomerular filtration rate.

Strengths

• 510 matched patient pairs provide a balanced cohort for comparative analysis.
• Includes longitudinal measurements for 6 key clinical indicators across a 24-month follow-up period.
• Explicitly documents statistical results, including p-values and confidence intervals for treatment differences.

Limitations

• The dataset is small at 183.5 KB, suggesting it contains summary results rather than raw patient-level records.
• As a retrospective study from only two centers in China, findings may have geographic and selection biases.
• Data is presented in a DOCX document format, which is not structured for direct computational analysis.

Provenance

Source

Zelin Yu via figshare.

Collection Method

Retrospective cohort study using propensity score matching on data extracted from institutional medical record systems.

Time Range

Patient data from January 2021 to October 2022, with 24-month follow-up.

Freshness

Last updated in March 2026.

Geography

Two medical centers in China.